Denver, Colorado- As markets open this morning, investor focus is gravitating toward execution stories, companies moving from promise to proof across medical robotics, advanced materials, and biotechnology.
Microbot Medical (NASDAQ:MBOT): Commercial Momentum Builds
Microbot Medical is drawing continued attention after shares have mostly traded higher since last week’s announcement that the company plans to leverage real-world physician experience with its LIBERTY Endovascular Robotic System at the Society of Interventional Oncology (SIO) annual meeting, taking place February 4–8, 2026, in Savannah, Georgia.
The timing is notable. The conference coincides with Microbot’s limited market release of LIBERTY, allowing the company to share practical insights and firsthand experiences from physicians already using the system across hospitals and procedure types. This also marks LIBERTY’s first commercial exhibition since the limited release began in late 2025, giving NASDAQ:MBOT direct access to interventional oncologists as it works to accelerate awareness and adoption.
LIBERTY is currently the only FDA-cleared, single-use, remotely operated robotic system designed for peripheral endovascular procedures. The platform is intended to improve precision while reducing radiation exposure and physical strain on physicians—factors that resonate strongly in interventional oncology, a field that has seen significant growth in procedure volumes over the past decade. Microbot plans a full market release at the Society of Interventional Radiology (SIR) conference in April 2026.
Kraig Biocraft Laboratories (OTCQB:KBLB): Turning the “Holy Grail” Into Reality
Kraig Biocraft Laboratories remains a focal point this morning following its announcement of a 2026 production plan targeting 10 metric tons of recombinant spider silk cocoon per month by May, a level of sustained output never before achieved.
Spider silk has long been considered a “holy grail” material due to its extraordinary combination of properties: it is stronger than steel by weight, tougher than Kevlar, highly flexible, lightweight, and biodegradable. These characteristics make it uniquely suited for high-performance textiles, advanced protective gear, medical sutures, next-generation composites, and even aerospace and defense applications. Despite its promise, commercial adoption has historically failed because spiders are territorial and cannibalistic, making farming impossible, and synthetic approaches proved too costly or inconsistent.
What differentiates OTCQB:KBLB is its silkworm-based recombinant platform, which genetically programs silkworms to produce spider silk proteins at scale. Over the past decade, companies and governments worldwide have collectively spent billions of dollars attempting, but failed to produce quality spider silk. Kraig Labs’ approach appears to have solved the scalability and consistency challenges that undermined those efforts.
Production is expected to begin within the next 30 days, with egg deployment starting in early March. The company has emphasized that its production strains have been refined through repeated rearing cycles to ensure industrial reliability, historically the biggest obstacle to commercialization.
Founder and CEO Kim Thompson called the initiative “the most exciting and ambitious program for spider silk production the world has ever seen,” highlighting that multi-ton output unlocks markets that were previously inaccessible.
Evommune (NYSE:EVMN): Phase 2a Data Strengthens the Story
Evommune delivered a significant clinical update this morning, announcing positive top-line results from its Phase 2a trial of EVO301 in adults with moderate-to-severe atopic dermatitis.
The trial met its primary endpoint, with EVO301 producing rapid, statistically significant reductions in Eczema Area and Severity Index (EASI) scores at weeks 4, 8, and 12 versus placebo. At week 12, the drug demonstrated a 33% placebo-adjusted improvement in EASI, and 23% of patients achieved IGA 0/1, compared to none in the placebo group.
Importantly for NYSE: EVMN, EVO301 was well tolerated, with no related serious or severe adverse events reported. Management described the data as a major milestone that validates IL-18 inhibition as a novel mechanism in atopic dermatitis and supports plans to advance the program into a Phase 2b dose-ranging trial.
ABPRO Holdings (NASDAQ:ABP): Institutional Interest Emerges
Rounding out the morning, ABPRO Holdings (NASDAQ:ABP) is trading higher in the pre-market following the disclosure of a Schedule 13G filing showing that Goldman Sachs Group (NYSE:GS) now beneficially owns 196,537 shares, representing a 6.8% stake in the company. The filing has put ABPRO on the radar as investors often view such ownership disclosures as a vote of confidence from institutional capital.
For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com
Please click here to read the full Kraig Labs analyst report on 247marketnews.com.
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider that owns KBLB shares, which are on deposit and may be sold at the editor’s discretion, and has been compensated for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions.
For further information, please visit 247marketnews.com or https://go.247marketnews.com/kblb-disclosure/
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.